Thomas Casdagli

Thomas joined MVM in 2002. Before joining MVM, he worked at PricewaterhouseCoopers’ Private Equity and Venture Capital practice. Thomas has an MBioch in Molecular and Cellular Biochemistry from Oxford University.

Thomas is a member of the boards of eXmoor Pharma Concepts Ltd and eZono GmbH. He was previously a director of Valneva SE (EPA: VLA), Alliance Pharma plc (AIM:APH), Lombard Medical Technologies plc (NASDAQ:EVAR), Heptares Ltd (acquired by Sosei Group Corporation), Avantium BV (AMS:AVTX), Onbone Oy, and Xention Pharma